Epigenetics Market

The epigenetics market is projected to reach USD 3.92 billion in 2031 from USD 2.22 billion in 2026, at a CAGR of 12.0% during the forecast period.

Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), and Revvity (US) are the key players in this market.

To know about the assumptions considered for the study download the pdf brochure

These market players have adopted various approaches, including product launches, collaborations, acquisitions, agreements, and expansions, to enhance their market positions. In January 2026, Illumina launched Connected Multiomics, a cloud-based research software platform for integrating and visualizing multimodal datasets, including genomics, transcriptomics, proteomics, and epigenetics. This supports downstream analysis of methylation and other epigenomic data with broader multiomics datasets.

In October 2025, Thermo Fisher launched SwiftArrayStudio, an integrated microarray analyzer designed to deliver results in as little as 30 hours and reduce hands-on time by up to 40%. The company specifically positioned the platform for future technology needs including methylation and epigenetics.

Thermo Fisher Scientific Inc. (US): Thermo Fisher Scientific offers a broad epigenetics portfolio covering sample preparation reagents, DNA methylation analysis kits, ChIP and chromatin preparation products, antibodies for histone modification studies, PCR/qPCR systems, NGS library preparation solutions, and bioinformatics tools. Its Applied Biosystems, Invitrogen, Ion Torrent, and Thermo Scientific offerings support workflows such as bisulfite conversion, methylation-specific PCR, ChIP-qPCR, ChIP-seq, ATAC-seq, and NGS-based epigenomic profiling. The company’s portfolio is widely used in oncology research, biomarker discovery, gene regulation studies, precision medicine, and translational research, helping laboratories generate reproducible epigenetic data across research and clinical development applications.

Illumina, Inc. (US): Illumina plays a major role in the epigenetics market through its sequencing platforms, methylation arrays, library preparation kits, sequencing reagents, and data analysis solutions. The company’s NovaSeq, NextSeq, MiSeq, and iSeq systems support epigenetic applications such as whole-genome bisulfite sequencing, targeted methylation sequencing, ChIP-seq, ATAC-seq, RNA-based epigenetic analysis, and single-cell epigenomic studies. Illumina’s Infinium methylation arrays are widely used for large-scale DNA methylation profiling in cancer research, population studies, biomarker discovery, and precision medicine. Its strong NGS ecosystem supports high-throughput, scalable, and genome-wide epigenetic analysis.

Merck KGaA (Germany): Merck, through its Life Science business, provides epigenetics products including chromatin immunoprecipitation kits, histone modification antibodies, DNA methylation analysis reagents, enzymes, nucleic acid purification products, buffers, and molecular biology consumables. Its MilliporeSigma portfolio supports workflows such as ChIP, ChIP-seq, methylated DNA analysis, chromatin remodeling studies, histone modification research, and downstream PCR or sequencing-based analysis. The company’s offerings are used by academic laboratories, pharmaceutical researchers, biotechnology companies, and CROs for gene regulation studies, cancer epigenetics, biomarker validation, and drug discovery research requiring reliable reagents and reproducible assay performance.

Market Ranking

The epigenetics market is competitive, with leading life sciences, sequencing, molecular biology, and bioinformatics companies driving technology adoption and workflow expansion. Key players include Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), and Merck KGaA (Germany). Thermo Fisher Scientific Inc. (US) offers a broad epigenetics portfolio covering DNA methylation analysis kits, chromatin immunoprecipitation products, histone modification antibodies, PCR/qPCR systems, NGS library preparation solutions, and bioinformatics tools, supporting workflows such as ChIP-seq, ATAC-seq, bisulfite sequencing, and methylation-specific PCR. Illumina, Inc. (US) strengthens the market through its sequencing platforms, methylation arrays, sequencing reagents, and data analysis solutions used for genome-wide methylation profiling, ChIP-seq, single-cell epigenomics, and multi-omics research. Merck KGaA (Germany) contributes through its Life Science business, offering ChIP kits, histone antibodies, DNA methylation reagents, enzymes, buffers, and molecular biology consumables used in gene regulation, chromatin remodeling, and biomarker research. Collectively, these companies support high-throughput epigenomic profiling, improve workflow reproducibility, and enable broader adoption of epigenetics technologies across pharmaceutical, biotechnology, academic, clinical, and CRO settings.

Related Reports:

Epigenetics Market by Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]